Boothbay Fund Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.31M | Buy |
54,567
+47,450
| +667% | +$2.77M | 0.04% | 437 |
|
|
2025
Q4 | $384K | Sell |
7,117
-2,364
| -25% | -$114K | 0.01% | 1286 |
|
|
2025
Q3 | $428K | Sell |
9,481
-20,083
| -68% | -$938K | 0.01% | 1256 |
|
|
2025
Q2 | $1.37M | Buy |
29,564
+20,214
| +216% | +$992K | 0.03% | 596 |
|
|
2025
Q1 | $570K | Sell |
9,350
-17,087
| -65% | -$996K | 0.02% | 810 |
|
|
2024
Q4 | $1.5M | Buy |
+26,437
| New | +$1.48M | 0.04% | 520 |
|
|
2023
Q4 | – | Sell |
-16,809
| Closed | -$976K | – | 1668 |
|
|
2023
Q3 | $976K | Buy |
+16,809
| New | +$1.03M | 0.02% | 784 |
|
|
2023
Q2 | – | Sell |
-73,944
| Closed | -$5.13M | – | 1842 |
|
|
2023
Q1 | $5.13M | Buy |
73,944
+68,956
| +1,382% | +$4.86M | 0.11% | 248 |
|
|
2022
Q4 | $359K | Sell |
4,988
-52,106
| -91% | -$3.93M | 0.01% | 1311 |
|
|
2022
Q3 | $4.06M | Buy |
+57,094
| New | +$4.14M | 0.1% | 255 |
|
|
2022
Q1 | – | Sell |
-48,439
| Closed | -$3.25M | – | 2286 |
|
|
2021
Q4 | $3.02M | Sell |
48,439
-24,137
| -33% | -$1.42M | 0.07% | 342 |
|
|
2021
Q3 | $4.29M | Sell |
72,576
-102,756
| -59% | -$6.77M | 0.12% | 197 |
|
|
2021
Q2 | $3.26M | Buy |
175,332
+34,680
| +25% | +$2.26M | 0.1% | 224 |
|
|
2021
Q1 | $736K | Buy |
140,652
+100,252
| +248% | +$6.24M | 0.03% | 744 |
|
|
2020
Q4 | $2.51M | Buy |
40,400
+14,972
| +59% | +$921K | 0.09% | 217 |
|
|
2020
Q3 | $1.53M | Sell |
25,428
-30,127
| -54% | -$1.81M | 0.09% | 298 |
|
|
2020
Q2 | $3.27M | Sell |
55,555
-3,191
| -5% | -$191K | 0.22% | 104 |
|
|
2020
Q1 | $3.27M | Buy |
58,746
+11,054
| +23% | +$676K | 0.27% | 90 |
|
|
2019
Q4 | $3.06M | Buy |
47,692
+33,361
| +233% | +$1.91M | 0.27% | 90 |
|
|
2019
Q3 | $727K | Buy |
+14,331
| New | +$674K | 0.07% | 379 |
|
|
2019
Q2 | – | Sell |
-13,656
| Closed | -$652K | – | 751 |
|
|
2019
Q1 | $652K | Buy |
+13,656
| New | +$680K | 0.06% | 313 |
|
|
2017
Q3 | – | Sell |
-4,096
| Closed | -$228K | – | 613 |
|
|
2017
Q2 | $228K | Sell |
4,096
-3,391
| -45% | -$185K | 0.05% | 510 |
|
|
2017
Q1 | $407K | Buy |
+7,487
| New | +$411K | 0.08% | 315 |
|
|
2016
Q4 | – | Sell |
-7,878
| Closed | -$425K | – | 766 |
|
|
2016
Q3 | $425K | Buy |
+7,878
| New | +$506K | 0.09% | 254 |
|
|
2016
Q2 | – | Sell |
-5,812
| Closed | -$371K | – | 513 |
|
|
2016
Q1 | $371K | Buy |
+5,812
| New | +$367K | 0.28% | 119 |
|
Other funds holding BMY
VCM
VPM
Boothbay Fund Management's BMY Position: Q1 2026 in Review
Boothbay Fund Management increased its Bristol-Myers Squibb (BMY) stake by 667% in Q1 2026, buying an estimated $2.77M and bringing the position to 54,567 shares worth $3.31M. The position accounts for 0.04% of the portfolio, ranked #437.
Boothbay Fund Management first reported a position in BMY in Q1 2016 and has held it in 25 quarters since. The position peaked at $5.13M in Q1 2023. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Boothbay Fund Management held 54,567 shares of Bristol-Myers Squibb worth $3.31M as of Q1 2026.
- Boothbay Fund Management bought 47,450 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.77M.
- Bristol-Myers Squibb made up 0.04% of Boothbay Fund Management's portfolio in Q1 2026, its #437 holding.
- Boothbay Fund Management first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 25 quarters since.
- Boothbay Fund Management's Bristol-Myers Squibb position peaked at $5.13M in Q1 2023.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.